Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQH2722 long-term safety in atopic dermatitis
CTR20233980Phase 2Completed
- Sponsor
- Jiangsu Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- Start
- Dec 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of TQH2722 in atopic dermatitis (AD), sponsored by Jiangsu Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.. Started Dec 2023; status: completed.
02
Drugs
TQH2722
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on CTR20233980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233980.